Rhythm Pharmaceuticals (RYTM) Prices 5M Share Common Offering at $30/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- Oil gains 3% as US-Iran peace talks in stalemate
- October Fed meeting hinges on this key economic data, Citi says
- Trump says men arrested at UK air base used by US were looking to do 'big damage'
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
- Oppenheimer sees AI software winners as focus shifts to ROI
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Dollar near two-month high as US-Iran stalemate bolsters oil, Fed rate hike bets
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering
February 4, 2021 9:49 PM ESTBOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced the pricing of its public offering of 5,000,000 shares of its common stock at a public offering price of $30.00 per share. All of the shares are being offered by Rhythm. In addition, Rhythm has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price, less the underwriting discount and commission. The... More
